Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab vs placebo after chemoradiotherapy in unresectable stage III NSCLC
CTR20181429Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in non-small cell lung cancer (NSCLC), sponsored by CStone Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20181429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181429.